Prot# CP-106: A Phase II Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Low to Intermediate Grade Neuroendocrine Carcinoma

Project: Research project

Project Details

StatusFinished
Effective start/end date5/21/07 → 11/1/11

Funding

  • Callisto Pharmaceuticals, Inc. (CP-106)